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ABSTRACT 
Objective: A gas chromatography (GC) method using flame ionization (FID) and mass spectrometry (MS) was developed and validated for the 
determination of nine local anaesthetics in counterfeit drugs sold illegally as treatments for male premature ejaculation.  
Methods: The GC-FID and GC-MS method validations demonstrated reliable specificity, selectivity, linearity, precision, and accuracy, and the 
validated methods were successfully applied to the analyses of collected samples. 
Results: Approximately 60% of the samples contained, at least, one of the local anaesthetics, which included menthol, 2-phenoxyethanol, eugenol, 
lidocaine, prilocaine, and tetracaine. Lidocaine was the most frequently detected compound in the analysed samples and occurred in a wide 
concentration range (2.81–52.40 mg/g). The concentrations of the detected compounds varied greatly between 0.03–52.40 mg/g. 
Conclusion: Continuous use of these counterfeit products, which contain high concentrations of local anaesthetics, can cause serious human health 
effects. Therefore, the continued screening of illegal products is required and our proposed methods could be used for the monitoring and 
quantification of local anaesthetics in counterfeit products.  
Keywords: Local anesthetics, Premature ejaculation, GC/FID, GC/MS, Adulterants, Validation. 
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INTRODUCTION 
Premature ejaculation (PE) is a highly prevalent sexual dysfunction 
among men [1-5]. Local anaesthetics are used for the treatment of PE, 
and are available as prescription drugs in South Korea. However, the use 
of drugs containing local anaesthetics in commercial products and the 
distribution of prohibited imported drugs are strictly controlled by the 
Korean government. Nevertheless, many illegal products containing local 
anaesthetics are distributed online or through sex shops in South Korea. 
Furthermore, many countries have reported the use of prohibited local 
anaesthetics in creams for the treatment of PE [6-10].  
Most people believe that these illegal products are safe because of 
incomplete product descriptions and insufficient information 
regarding their contraindications, and they deny that they have 
taken an illegal medicinal product [11]. Moreover, illegal products 
can contain high doses of prohibited ingredients [12]. The abuse of 
local anaesthetics can cause side effects, such as erectile dysfunction, 
hypersexuality, a decrease in arousal, numbness, dermatitis, and 
contamination of their partner’s vagina [7]. These effects result in 
unpredictable risks to health and safety [11, 13]. Therefore, the 
increased use of illegal products containing local anaesthetics has 
necessitated the development of methods for simultaneous 
detection and continuous monitoring of these adulterants [13]. 
Few analytical methods for the determination of adulterated local 
anaesthetics have been described in the literature. Porra et al. 
developed a high-performance liquid chromatography (HPLC) 
method using solid-phase extraction for the identification of five 
local anaesthetics in commercial products [14]. An HPLC method 
using an ultraviolet diode array (UV-DAD) and electro spray 
ionization mass spectrometry (ESI-MS) was reported for the 
determination of prilocaine, procaine, benzocaine, and lidocaine in 
creams by Orsi et al. [6]. Additionally, the analysis of lidocaine as an 
adulterant in cocaine-based products was performed using HPLC-
DAD [13]. Although some methods for the analysis of local 
anaesthetics have been proposed, none has described a validated 
method using GC-FID and GC-MS for the identification and 
quantification of local anaesthetic adulterants in seized creams that 
were sold illegally for the purpose of PE treatment.  
Our aim was to develop and validate a method based on GC-FID and 
GC-MS for the monitoring of nine local anaesthetics in suspicious 
products. In addition, we assessed our validated method for its 
applicability in real samples of seized products that were advertised 
to strengthen male sexual function, especially PE, from online 
retailers and sex shops. 
MATERIALS AND METHODS 
Solvents and chemicals 
Eugenol was purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA). 
Lidocaine, 2-phenoxyethanol, menthol, procaine hydrochloride, 
benzocaine hydrochloride, bupivacaine hydrochloride, prilocaine 
hydrochloride, and tetracaine hydrochloride were obtained from U. S. 
Pharmacopeia (Rockville, MD, USA). Methanol (HPLC grade) was 
obtained from Merck (Darmstadt, Germany).  
Preparation of stock and standard solutions 
Stock solutions of the nine compounds were prepared in methanol at 
concentrations of 1000 µg/ml and stored at 4 °C. Furthermore, the 
working standard solutions (100 µg/ml) were prepared daily by 
dilution of the stock solutions with methanol. Calibration standard 
solutions for GC-FID and GC-MS methods were prepared using 
working standard solutions in the concentration ranges of 5–100 
µg/ml, i.e.,5, 10, 20, 40, 80, and 100 µg/ml, and 0.5–10 µg/ml, i.e., 
0.5, 1, 2, 4, 8, and 10 µg/ml, respectively. 
Samples and extraction 
The products advertised the ability to improve and strengthen male 
sexual capacity and were obtained from online retailers and sex 
shops. The 26 samples that were collected consisted of creams (17), 
gels (6), and sprays (3). The samples (1 g) were diluted in methanol 
(50 ml) and extracted using sonication for 30 min. All of the extracts 
were filtered through a 0.22 µm polytetrafluoroethylene (PTFE) 
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syringe filter (Whatman International Ltd., Maidstone, Kent, UK) 
before injection into the GC-FID and GC-MS systems. 
GC-FID operating conditions 
An Agilent 7890A GC system (Agilent Technologies Inc., Santa Clara, 
USA) equipped with a 7693 auto sampler and a flame ionization 
detector (FID) was used for the analysis. Separation was achieved 
using a J&W Scientific DB-5 column (length 50 m, internal diameter 
0.25 mm, film thickness 0.25 µm) that was obtained from Agilent (CA, 
USA). The oven temperature was programmed to increase from 100–
200 °C at a rate of 15 °C/min, then from 200–300 °C at a rate of 5 
°C/min, where it was held constant for 8 min. The injection volume 
was 1 µl and a split (10:1) inlet mode was used. The inlet and detector 
temperatures were set to 250 and 300 °C, respectively. N2 was used as 
the make-up gas and the carrier gas (N2
An Agilent 7890A GC system (Agilent Technologies Inc., Santa Clara, 
USA) interfaced with a 5975C MSD, a 7683 auto sampler, and Agilent 
chem station software was used. The MS tuning was performed daily 
using a perfluoro-tributylamine (PFTBA) standard, which consisted 
of masses 69, 219, and 502 m/z. The temperature of transfer line 
was maintained at 280 °C. A 1 µl aliquot of a sample was injected 
using a split mode (10:1) at 250 °C. A DB-5 column (length 30 m, 
internal diameter 0.25 mm, film thickness 0.25 µm; J&W Scientific, 
Agilent, CA, USA) was used for the separation and the carrier gas was 
high-purity helium (99.9999%) at a flow rate 1.5 ml/min. The initial 
oven temperature was 100 °C, which was increased to 200 °C at a 
rate of 15 °C/min, and then increased to 300 °C at a rate of 5 °C/min, 
where it was held constant for 8 min. The samples were ionized in 
an electron ionization (EI) mode at 70 eV. The MS source and quad 
temperatures were set to 230 °C and 150 °C, respectively. The mass 
spectra were identified over the 50–500 m/z mass range in full scan 
(SCAN) mode. Quantitation was determined in selected ion 
monitoring mode (SIM mode) by the major ions for menthol, 2-
phenoxyethanol, eugenol, benzocaine hydrochloride, tetracaine 
hydrochloride and bupivacaine hydrochloride at m/z 71, 94, 164, 
120, 58 and 140. The major ions for prilocaine hydrochloride, 
lidocaine and procaine hydrochloride were m/z 86 (table 1).  
) flow rate was 1.0 ml/min.  
GC-MS operating and conditions 
 
Table 1: Diagnostic ions and retention times of the local anaesthetics in the GC-MS 
S. No.  Compound Retention time (min) Diagnostic ions (m/z) 
1 Menthol 3.671 71, 81, 95 
2 2-Phenoxyethanol 3.955 94, 77, 138 
3 Eugenol 5.013 164, 149, 131 
4 Benzocaine hydrochloride 6.827 120, 165, 92 
5 Prilocaine hydrochloride 9.324 86, 106, 77 
6 Lidocaine 9.733 86, 58, 87 
7 Procaine hydrochloride 11.667 86, 99, 120 
8 Tetracaine hydrochloride 14.455 58, 71, 176 
9 Bupivacaine hydrochloride 15.065 140, 141, 84 
 
Validation method 
The two methods were validated using parameters, such as the 
specificity, selectivity, linearity, limits of detection and quantification 
(LOD and LOQ), precision, accuracy, recovery, and stability based on 
the International Conference on Harmonisation (ICH) [15-17]. Ten 
products (eight creams and two gels), which were not adulterated 
with local anaesthetics, were used as matrix-blank samples for the 
validation evaluation. Both matrix-blank sample types were assayed to 
confirm their specificity and selectivity. The linearity of the method 
was studied using an external standardization. The six calibration 
standard solutions were analysed in triplicate. The calibration curves 
were plotted using the peak areas corresponding to each compound 
versus their concentrations. The LODs and LOQs, calculated at signal-
to-noise ratios of 3 and 10, respectively, were calculated using peak-to-
peak signal-to-noise ratios across a concentration range of 0.1–1.0 
µg/ml spiked into the matrix blank sample types. The precision, 
accuracy, recovery and stability were evaluated at three different (low, 
medium, and high) concentrations, i.e., 5, 40, and 100 µg/ml for GC-FID, 
and 0.5, 4, and 10 µg/ml for GC-MS. The precisions were determined by 
intra-and interday repeatability and expressed as their relative standard 
deviations (%RSD). The repeatability was evaluated by performing three 
replicate analyses at the three different concentrations during the same 
day. The intermediate precisions were evaluated using analyses at the 
three different concentrations in triplicate per day over three days. The 
accuracy was calculated by comparing the calculated and standard 
concentrations spiked into the matrix blank sample. The recoveries were 
evaluated using the matrix blank sample types that were spiked with the 
standards at three different concentrations. The average percent 
recoveries were calculated by comparing the peak areas of the spiked 
samples and the standard at their corresponding concentrations. The 
stability was evaluated using three replicate injections under the process 
conditions. A standard solution mixture was analysed every 24 h at 
ambient temperature for 48 h.  
RESULTS AND DISCUSSION 
Identity 
Standard addition experiments were used for confirmation using 
GC-FID. The retention times, mass spectra, and m/z ratios of each 
analyte obtained from GC-MS in SCAN mode were compared for the 
identification of each analyte, and the spectrum match factors 
obtained from the NIST Identity Spectrum Search algorithm (NIST 
MS Search 2.0 ver. D) were used to evaluate the quality of the mass 
spectra of each analyte. 
Specificity and selectivity 
Matrix-blank sample types spiked with 5 µg/ml of the standard 
mixture were analysed. The results confirmed that the 
chromatograms generated from the GC-FID (fig.1) and GC-MS (fig.2) 
methods experienced no significant interference, nor the co-elution 
of any of the analytes. The mass spectra generated using the MS 
detection system was used for the chromatographic selectivity 
assessment. The similarities of the mass spectra of the analytes and 
from libraries were compared. Our method indicated that the 
similarity was >90% and it was considered selective. 
Linearity, LOD and LOQ 
The linearity of the method was evaluated in triplicate over linear 
concentration ranges of 5–100 µg/ml and 0.5–10 µg/ml at six 
different levels for the GC-FID and GC-MS methods, respectively. 
Calibration curves were obtained using the peak area responses of 
the standard solutions. The correlation coefficients (R2
Precision, accuracy and recovery 
) of each of 
the compounds obtained from both the GC-FID and GC-MS 
methods were>0.99 (table 2). The LOD and LOQ were considered 
to be three and ten times the signal-to-noise ratio, respectively, 
using matrix-blank samples spiked with the standards. The LOD 
and LOQ for the nine compounds from the GC-FID and GC-MS 
methods are given in table 2. 
The precision determined by intraday repeatability, the 
intermediate interday precision, and the accuracy values are 
reported in table 3. Intra-and interday assays were performed as 
nine analyses in the same day (three replications each for three 
concentrations) and as an independent analysis per day over 3 d, 
respectively. The %RSD ranged from 0.54–10.34% and 0.19–2.86% 
for inter-and intraday measurements, respectively, using the GC-FID 
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method. The RSD% values of GC-MS method were<11% for both the 
repeatability and intermediate precision. As seen in table 3, the 
accuracy ranged between 83.90–119.58% from intra and interday 
assays using the GC-FID and GC-MS methods. The average recoveries 
of the methods ranged between 80.13–118.89% and the %RSD of 
the average recoveries were<13% for all of the compounds (table 4).
  
 
Fig. 1: GC-FID chromatograms of (A) a matrix-blank sample and (B) a sample spiked with standard at the limit of quantification 
 
 
Fig. 2: GC-MS extracted ion chromatograms of (A) a matrix-blank sample and (B) a sample spiked with standard at the limit of 
quantification 
  
Table 2: Correlation coefficients and the limits of detection and quantification (LOD and LOQ) for local anaesthetics by GC-FID and GC-MS 
S. No. Compounds GC-FID GC-MS 


















1 Menthol 0.999 0.17 0.52 0.17 0.52 0.997 0.03 0.10 0.04 0.13 
2 2-Phenoxyethanol 0.999 0.23 0.69 0.46 1.37 0.995 0.04 0.11 0.05 0.14 
3 Eugenol 0.999 0.33 1.00 0.17 0.50 0.993 0.18 0.54 0.09 0.27 
4 Benzocaine hydrochloride 0.999 0.35 1.05 0.35 1.05 0.993 0.09 0.26 0.13 0.38 
5 Prilocaine hydrochloride 0.998 1.02 3.07 0.34 1.02 0.994 0.10 0.31 0.26 0.77 
6 Lidocaine 1.000 0.34 1.02 0.34 1.02 0.991 0.09 0.26 0.09 0.26 
7 Procaine hydrochloride 0.999 1.04 3.13 0.69 2.08 0.992 0.17 0.51 0.09 0.26 
8 Tetracaine hydrochloride 0.999 1.04 3.13 0.69 2.08 0.991 0.17 0.50 0.17 0.50 
9 Bupivacaine hydrochloride 1.000 1.03 3.10 0.69 2.07 0.991 0.08 0.25 0.08 0.25 
a LOD, limit of detection; LOQ, limit of quantification, n=3. 
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Table 3: GC-FID and GC-MS precisions and accuracies for the local anaesthetics 
S. No. Compounds Conc. 
(ppm) 
a GC-FID GC-MS 



















Menthol low 117.08 0.50 108.82 7.39 95.54 5.55 98.47 2.21 
medium 99.80 0.65 102.77 7.40 88.41 3.05 89.31 3.68 
high 99.09 0.92 103.15 7.05 98.42 5.32 97.75 5.56 
2 2-Phenoxyethanol low 110.28 0.51 107.64 5.53 96.50 3.69 99.33 2.24 
medium 98.48 0.47 98.87 4.32 86.32 2.53 87.72 2.98 
high 98.66 0.99 100.17 3.75 100.43 5.77 99.74 4.24 
3 Eugenol low 84.04 1.30 89.59 10.34 97.63 2.17 101.14 1.05 
medium 90.29 0.65 88.02 2.34 83.79 1.83 84.01 4.26 
high 96.06 0.80 94.98 1.24 104.07 5.83 101.53 3.63 
4 Benzocaine 
hydrochloride 
low 102.86 0.61 100.16 6.78 95.79 3.94 96.97 5.42 
medium 96.03 0.82 97.47 6.21 85.76 0.83 85.34 3.13 
high 96.05 1.14 98.40 5.68 105.56 4.63 102.46 3.37 
5 Prilocaine 
hydrochloride 
low 90.92 2.86 119.23 6.91 98.16 2.16 95.23 5.89 
medium 111.16 0.27 107.61 3.51 84.65 0.68 84.81 7.81 
high 115.27 1.07 111.99 4.23 97.86 4.72 97.38 7.33 
6 Lidocaine low 89.27 1.39 86.97 4.71 96.68 3.59 99.66 3.54 
medium 93.66 0.36 96.10 4.84 85.47 0.98 85.08 3.59 
high 95.14 1.07 98.63 4.61 106.61 5.32 103.55 3.60 
7 Procaine 
hydrochloride 
low 116.08 1.70 114.60 2.25 96.78 3.74 90.48 10.98 
medium 98.47 1.01 99.10 0.58 83.90 1.13 84.09 8.13 
high 96.72 0.24 96.84 0.57 98.37 3.86 97.30 8.54 
8 Tetracaine 
hydrochloride 
low 113.69 1.46 110.19 5.66 98.42 4.16 93.78 6.45 
medium 93.40 0.99 93.82 0.54 84.17 1.28 84.62 7.94 
high 91.41 0.30 91.48 0.61 95.85 3.27 96.61 8.79 
9 Bupivacaine 
hydrochloride 
low 118.76 1.42 119.58 0.77 99.71 1.97 97.77 4.63 
medium 97.77 1.06 100.12 2.16 87.07 0.83 86.84 4.30 
high 95.11 0.19 96.62 1.37 99.66 3.83 99.35 6.08 
a Conc, concentration, b n=9, c
 
 %RSD, percentage relative standard deviation. 
Table 4: GC-FID and GC-MS recoveries (%) of the local anaesthetics in the matrix-blank samples 
S. No. Compounds  GC-FID GC-MS 
Conc. 
(ppm) 
a Cream Gel Cream Gel 
Recovery %RSDb Recoveryc %RSDb Recoveryc %RSDb Recoveryc %RSDb 
1 
c 
Menthol low 116.53 1.06 113.94 0.47 94.09 6.58 86.91 6.33 
medium 111.13 0.62 111.49 0.74 95.03 4.25 94.10 3.63 
high 110.20 0.42 108.63 0.41 98.74 9.15 101.75 10.42 
2 2-Phenoxyethanol low 116.98 1.10 111.08 1.44 119.97 6.61 99.40 5.50 
medium 108.68 0.60 108.44 0.64 102.72 3.18 104.97 2.98 
high 106.81 0.45 105.54 0.38 104.34 9.76 111.04 11.77 
3 Eugenol low 97.87 1.20 101.35 0.41 111.67 4.06 97.01 2.52 
medium 91.72 0.59 96.72 0.78 117.52 4.27 107.51 4.08 
high 89.93 0.42 93.81 0.39 99.47 7.78 96.07 13.00 
4 Benzocaine hydrochloride low 116.06 1.05 114.04 1.07 102.67 3.73 118.89 6.24 
medium 108.69 0.60 111.92 0.86 100.01 3.91 97.26 4.61 
high 107.11 0.38 108.14 0.64 108.09 9.24 108.97 12.32 
5 Prilocaine hydrochloride low 111.43 1.25 112.85 0.89 96.71 3.23 91.23 0.65 
medium 102.97 0.53 107.60 0.83 94.87 1.17 96.23 2.32 
high 99.19 0.41 101.21 0.75 100.07 10.55 92.85 12.03 
6 Lidocaine low 109.46 1.22 112.90 0.53 96.86 2.25 92.88 0.72 
medium 104.83 0.64 109.54 0.91 95.73 1.41 97.63 3.10 
high 103.74 0.37 105.62 0.74 106.77 10.93 91.33 12.29 
7 Procaine hydrochloride low 99.01 4.15 86.54 4.77 98.92 4.61 112.38 9.25 
medium 98.02 1.20 80.13 2.84 96.33 0.83 101.18 9.11 
high 101.67 0.12 88.44 0.57 105.78 9.39 107.08 12.20 
8 Tetracaine hydrochloride low 104.40 0.80 107.79 1.13 104.70 2.91 104.96 4.01 
medium 97.08 0.72 101.09 0.93 97.52 0.74 98.38 1.56 
high 95.31 0.37 96.45 0.76 101.40 8.07 102.56 11.79 
9 Bupivacaine hydrochloride low 112.69 3.41 113.51 1.85 95.83 2.22 89.24 0.50 
medium 107.40 1.42 113.54 0.15 95.99 0.33 93.31 1.80 
high 105.96 0.28 108.64 1.19 98.54 8.46 100.47 11.16 
a Conc, concentration, b n=3., c
 
Stability 
 %RSD, percentage relative standard deviation. 
The stabilities of the standard solutions, which were stored at 4 °C, 
were evaluated by their comparison with the peak areas detected 
from freshly prepared standard solutions. The stability experiments 
were performed in the auto sampler (20 °C) at three concentrations 
over 48 h. Table 5 summarizes that an averaged %RSD of the 
stabilities were within 13%. Therefore, all of the stock solutions 
were considered to have reliable stability under normal working 
conditions.
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Table 5: Stability of the standard stock solutions 
S. No. Compounds Conc. 
(ppm) 
a GC-FID GC-MS 
(%RSDb (%RSD) b) 
1 Menthol low 1.56 2.11 
medium 2.21 2.28 
high 1.52 1.42 
2 2-Phenoxyethanol low 7.13 1.02 
medium 2.19 2.29 
high 1.80 1.69 
3 Eugenol low 4.17 3.06 
medium 2.15 3.93 
high 1.78 2.00 
4 Benzocaine hydrochloride low 12.42 8.46 
medium 2.01 3.61 
high 1.99 1.56 
5 Prilocaine hydrochloride low 7.31 10.81 
medium 1.35 6.40 
high 1.97 3.14 
6 Lidocaine low 2.77 6.28 
medium 2.26 3.51 
high 2.04 1.25 
7 Procaine hydrochloride low 10.98 8.52 
medium 1.68 12.34 
high 3.15 4.55 
8 Tetracaine hydrochloride low 9.34 14.09 
medium 1.34 4.92 
high 2.85 6.08 
9 Bupivacaine hydrochloride low 3.72 8.70 
medium 2.06 5.22 
high 2.15 1.37 
a Conc, concentration., b
 
 %RSD, percentage relative standard deviation; n=3. 
Analysis of the seized samples 
The developed and validated GC-FID and GC-MS methods were applied 
to the screening for the presence of local anaesthetics and their 
quantification in 26 products collected from online retailers or sex 
shops in South Korea. Approximately 60% (16/26) of the samples 
were adulterated with some of the local anaesthetics (table 6). The 
local anaesthetics that were detected in the samples were menthol, 2-
phenoxyethanol, eugenol, prilocaine, tetracaine, and lidocaine. The 
most frequently detected adulterant was lidocaine, which was found in 
58% (15/26) of the samples. Its concentration ranged between 2.81–
52.40 mg/g. Eugenol and prilocaine were only detected in each 
samples. Three of the samples (12%) contained both menthol and 2-
phenoxyethanol. Also, more than one local anaesthetic was detected in 
some of the analysed products. Menthol (0.03–0.16 mg/g) and 2-
phenoxyethanol (0.20–0.21 mg/g) were found in combination with 
lidocaine (2.81–9.68 mg/g) in two samples, and menthol (7.89 mg/g) 
and 2-phenoxyethanol (3.19 mg/g) were in combination with eugenol 
(3.45 mg/g) in one sample. Tetracaine (52.20 mg/g) and lidocaine 
(33.00 mg/g) were detected in combination with prilocaine (12.80 
mg/g) in one sample, and tetracaine (18.30 mg/g) was found in 
combination with lidocaine (34.80 mg/g) in another sample. However, 
three of the compounds (benzocaine, procaine, and bupivacaine) were 
not detected in any of these illegal products. 
CONCLUSION 
There was limited preliminary literature regarding the analysis of local 
anaesthetics in creams. However, a study on the presence of adulterant 
local anaesthetics in products advertised for strengthening male sexual 
function using GC-FID and GC-MS has never been published.  
In this study, we validated a GC-FID method for the identification 
and quantification of local anaesthetics in illegal product samples. 
This method allowed the clear separation of each suspected 
compound and provided stable values during the analysis 
procedure. It could be routinely performed in most laboratories. 
Further study using GC-MS allowed for the confirmation of the trace 
local anaesthetics by their mass spectra, and it would be possible to 
screen suspicious compounds including local anesthetics in 
counterfeit products. 
Our suggested methods were applied to the detection of seized 
illegal products that included local anaesthetics, and more than half 
of the analysed samples contained illegal local anaesthetics whose 
concentrations were quite high. We consider the screening and 
identification of adulterants in illegally distributed products 
important because the undeclared components of illicit creams or 
counterfeit products can cause health problems.  
We anticipate that the proposed combination of methods used in 
this study would facilitate the screening of local anaesthetic 
adulterants, which are included in numerous unknown products 
advertised as treatment or improvements for PE. These studies in 
the field of forensic science will contribute to the strict regulations of 
these illegal products and the public health.  
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